BlackRock’s HilleVax HLVX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-387,533
| Closed | -$771K | – | 5512 |
|
|
2025
Q2 | $771K | Sell |
387,533
-1,707,979
| -82% | -$3.12M | ﹤0.01% | 4341 |
|
|
2025
Q1 | $3.04M | Sell |
2,095,512
-67,775
| -3% | -$125K | ﹤0.01% | 3854 |
|
|
2024
Q4 | $4.48M | Buy |
2,163,287
+29,234
| +1% | +$54.9K | ﹤0.01% | 3770 |
|
|
2024
Q3 | $3.76M | Buy |
2,134,053
+43,449
| +2% | +$111K | ﹤0.01% | 3812 |
|
|
2024
Q2 | $30.2M | Buy |
2,090,604
+290,327
| +16% | +$3.99M | ﹤0.01% | 2729 |
|
|
2024
Q1 | $29.9M | Buy |
1,800,277
+24,340
| +1% | +$389K | ﹤0.01% | 2761 |
|
|
2023
Q4 | $28.5M | Buy |
1,775,937
+488,355
| +38% | +$6.49M | ﹤0.01% | 2806 |
|
|
2023
Q3 | $17.3M | Buy |
1,287,582
+17,110
| +1% | +$241K | ﹤0.01% | 3019 |
|
|
2023
Q2 | $21.8M | Buy |
1,270,472
+232,625
| +22% | +$3.61M | ﹤0.01% | 2992 |
|
|
2023
Q1 | $17.2M | Buy |
1,037,847
+9,374
| +0.9% | +$150K | ﹤0.01% | 3053 |
|
|
2022
Q4 | $17.2M | Buy |
1,028,473
+256,419
| +33% | +$4.63M | ﹤0.01% | 3114 |
|
|
2022
Q3 | $13.2M | Buy |
772,054
+34,872
| +5% | +$507K | ﹤0.01% | 3270 |
|
|
2022
Q2 | $8.06M | Buy |
+737,182
| New | +$8.75M | ﹤0.01% | 3608 |
|
BlackRock's HLVX Position: Q3 2025 in Review
BlackRock sold out of HilleVax (HLVX) in Q3 2025, closing a stake of 387,533 shares — an estimated $771K sold.
BlackRock first reported a position in HLVX in Q2 2022 and held it in 13 quarters. The position peaked at $30.2M in Q2 2024. 1 fund tracked by Wall St. Rank holds HLVX as of Q3 2025.
- BlackRock reported no remaining HilleVax position as of Q3 2025 after selling out during the quarter.
- BlackRock sold 387,533 HilleVax shares in Q3 2025, an estimated $771K.
- BlackRock first reported a position in HilleVax in Q2 2022 and held it in 13 quarters.
- BlackRock's HilleVax position peaked at $30.2M in Q2 2024.
- 1 fund tracked by Wall St. Rank held HilleVax as of Q3 2025.
Based on BlackRock's 13F filing for Q3 2025, filed 12 Nov 2025.